TrialNature medicine2023

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.

Raffit Hassan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.